Loading...
XASXACR
Market cap8mUSD
Jan 02, Last price  
0.03AUD
1D
0.00%
1Q
-38.89%
Jan 2017
-89.35%
Name

Acrux Ltd

Chart & Performance

D1W1MN
XASX:ACR chart
P/E
—
P/S
2.61
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
11.69%
Rev. gr., 5y
51.83%
Revenues
5m
-39.60%
2,711,090517,0002,897,0003,841,000650,00054,904,00089,603,0008,797,00015,549,00053,859,00025,368,00028,557,00023,934,0003,432,000631,0001,253,0001,337,0001,719,0008,429,0005,091,000
Net income
-6m
L+659.16%
23,965-9,940,000-7,860,000-5,026,000-7,716,00046,554,00057,148,0007,391,0006,926,00027,970,00011,130,00012,981,000-243,000-14,182,000-8,324,999-9,471,000-12,629,000-9,834,000-764,000-5,800,000
CFO
-4m
L
-5,902,160-8,226,000-7,698,000-2,713,000-5,781,00048,119,00065,104,000-2,432,0006,335,00036,371,00010,519,00016,506,0005,376,000-5,282,000-9,938,000-8,533,000-11,414,000-8,819,000703,000-4,303,000
Dividend
Aug 18, 20150.0857142857 AUD/sh
Earnings
Feb 25, 2025

Profile

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. The company was incorporated in 1998 and is based in West Melbourne, Australia.
URL
https://www.acrux.com.au/
IPO date
Sep 29, 2004
Employees
43
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
5,091
-39.60%
8,429
390.34%
1,719
28.57%
Cost of revenue
14,567
11,819
20,396
Unusual Expense (Income)
NOPBT
(9,476)
(3,390)
(18,677)
NOPBT Margin
Operating Taxes
232
(2,825)
(3,114)
Tax Rate
NOPAT
(9,708)
(565)
(15,563)
Net income
(5,800)
659.16%
(764)
-92.23%
(9,834)
-22.13%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,780
192
224
Long-term debt
4,141
4,322
3,708
Deferred revenue
(1)
Other long-term liabilities
41
38
40
Net debt
2,976
(1,718)
(4,455)
Cash flow
Cash from operating activities
(4,303)
703
(8,819)
CAPEX
(276)
(119)
(465)
Cash from investing activities
(276)
(119)
(465)
Cash from financing activities
1,292
(183)
(155)
FCF
(9,160)
(970)
(15,823)
Balance
Cash
2,945
6,232
5,831
Long term investments
2,556
Excess cash
2,690
5,811
8,301
Stockholders' equity
3,276
8,696
9,090
Invested Capital
4,331
5,276
2,907
ROIC
ROCE
EV
Common stock shares outstanding
289,500
286,461
283,882
Price
0.07
64.29%
0.04
-19.23%
0.05
-60.00%
Market cap
19,975
66.03%
12,031
-18.50%
14,762
-48.32%
EV
22,951
10,313
10,307
EBITDA
(8,966)
(2,795)
(18,017)
EV/EBITDA
Interest
Interest/NOPBT